10,183 Shares in DexCom, Inc. (NASDAQ:DXCM) Purchased by Brooktree Capital Management

Brooktree Capital Management bought a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 10,183 shares of the medical device company’s stock, valued at approximately $683,000. DexCom makes up 0.6% of Brooktree Capital Management’s portfolio, making the stock its 22nd biggest holding.

A number of other institutional investors have also recently made changes to their positions in the company. Crewe Advisors LLC purchased a new position in DexCom in the 1st quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of DexCom in the second quarter valued at about $25,000. Sachetta LLC lifted its stake in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares in the last quarter. DT Investment Partners LLC boosted its position in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after acquiring an additional 315 shares during the last quarter. Finally, Riverview Trust Co grew its stake in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of research reports. Royal Bank of Canada decreased their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Morgan Stanley lowered their price objective on DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Friday, July 26th. Raymond James dropped their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Robert W. Baird lifted their price target on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th. Finally, Leerink Partners dropped their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Stock Performance

Shares of DXCM stock opened at $72.75 on Thursday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm’s 50 day moving average price is $69.72 and its 200-day moving average price is $92.27. The firm has a market cap of $28.42 billion, a P/E ratio of 43.43, a P/E/G ratio of 2.28 and a beta of 1.17.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.